- Home
- FTFT vs NCNA Comparison
FTFT vs NCNA Comparison
Compare FTFT & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- NCNA
- Stock Information
- Founded
- FTFT N/A
- NCNA 1997
- Country
- FTFT United States
- NCNA United Kingdom
- Employees
- FTFT N/A
- NCNA N/A
- Industry
- FTFT Business Services
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- NCNA Health Care
- Exchange
- FTFT Nasdaq
- NCNA Nasdaq
- Market Cap
- FTFT 3.9M
- NCNA 4.5M
- IPO Year
- FTFT N/A
- NCNA 2017
- Fundamental
- Price
- FTFT $1.53
- NCNA $0.55
- Analyst Decision
- FTFT
- NCNA Buy
- Analyst Count
- FTFT 0
- NCNA 2
- Target Price
- FTFT N/A
- NCNA $25.00
- AVG Volume (30 Days)
- FTFT 82.2K
- NCNA 143.6K
- Earning Date
- FTFT 04-15-2025
- NCNA 05-15-2025
- Dividend Yield
- FTFT N/A
- NCNA N/A
- EPS Growth
- FTFT N/A
- NCNA N/A
- EPS
- FTFT N/A
- NCNA N/A
- Revenue
- FTFT $2,158,125.00
- NCNA N/A
- Revenue This Year
- FTFT N/A
- NCNA N/A
- Revenue Next Year
- FTFT N/A
- NCNA N/A
- P/E Ratio
- FTFT N/A
- NCNA N/A
- Revenue Growth
- FTFT N/A
- NCNA N/A
- 52 Week Low
- FTFT $1.15
- NCNA $0.69
- 52 Week High
- FTFT $9.00
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- FTFT 47.43
- NCNA 35.90
- Support Level
- FTFT $1.28
- NCNA $0.71
- Resistance Level
- FTFT $1.49
- NCNA $0.89
- Average True Range (ATR)
- FTFT 0.17
- NCNA 0.09
- MACD
- FTFT 0.05
- NCNA -0.02
- Stochastic Oscillator
- FTFT 86.36
- NCNA 0.00
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and cryptocurrency mining farm in the U.S. The company's reportable segments include the Supply chain financing/trading segment which generates key revenue, and the Asset management service segment.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.